Literature DB >> 3499815

Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use.

E N Larkai1, J L Smith, M D Lidsky, D Y Graham.   

Abstract

Gastroduodenal intolerance is one of the major factors limiting the use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAID) in patients with arthritic conditions. We evaluated the endoscopic appearance of the gastroduodenal mucosa in 65 patients (63 men and two women) taking regular daily doses of NSAIDs over a long period for osteoarthritis or rheumatoid arthritis. Eight different drugs (indomethacin, ibuprofen, naproxen, sulindac, piroxicam, aspirin, salsalate, and tolmetin) had been taken continuously for at least 6 wk. Seven patients took two different NSAIDs. No other drug known to damage the mucosa was used. Twenty-one patients (32%) had an endoscopically completely normal stomach and duodenum, and 44 (68%) had evidence of injury (mucosal hemorrhage 44.6%, erosions 53.8%, both mucosal hemorrhage and erosions 34%). Ten patients had ulcers detected (seven gastric, two pyloric channel, one duodenal bulb) for a point prevalence of 15.4%. Ulcers were found in patients taking naproxen, indomethacin, tolmetin, sulindac, and ibuprofen, either alone, or in combination with aspirin. Dyspeptic symptoms were present in 19% of those with completely normal endoscopy and in only 9% of those with abnormal endoscopic findings. Only three of the 10 patients with ulcer had dyspeptic symptoms. There was no significant difference between drugs in tendency to cause gastroduodenal injury. We confirm that fairly severe gastroduodenal injury occurs in asymptomatic patients with rheumatoid and osteoarthritis, and that symptoms do not predict the presence of damage.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3499815

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  69 in total

1.  Prevention of acute NSAID-related gastroduodenal damage: a meta-analysis of controlled clinical trials.

Authors:  G Leandro; A Pilotto; M Franceschi; T Bertin; E Lichino; F Di Mario
Journal:  Dig Dis Sci       Date:  2001-09       Impact factor: 3.199

Review 2.  [Therapy with nonsteroidal anti-inflammatory drugs].

Authors:  H Bauer; E Märker-Hermann
Journal:  Orthopade       Date:  2003-12       Impact factor: 1.087

Review 3.  NSAIDs. Safety implications of over-the-counter availability.

Authors:  S Meckstroth; M Schwartz; N Agrawal
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

Review 4.  Non-steroidal anti-inflammatory drugs and peptic ulcers.

Authors:  C J Hawkey
Journal:  BMJ       Date:  1990-02-03

5.  Zinc carnosine, a health food supplement that stabilises small bowel integrity and stimulates gut repair processes.

Authors:  A Mahmood; A J FitzGerald; T Marchbank; E Ntatsaki; D Murray; S Ghosh; R J Playford
Journal:  Gut       Date:  2006-06-15       Impact factor: 23.059

Review 6.  Epidemiology of NSAID-induced gastropathy.

Authors:  H Zeidler
Journal:  Clin Rheumatol       Date:  1991-12       Impact factor: 2.980

Review 7.  Coming to terms with nonsteroidal anti-inflammatory drug gastropathy.

Authors:  Sanford H Roth
Journal:  Drugs       Date:  2012-05-07       Impact factor: 9.546

Review 8.  Gastrointestinal Perforations with Biologics in Patients with Rheumatoid Arthritis: Implications for Clinicians.

Authors:  Aprajita Jagpal; Jeffrey R Curtis
Journal:  Drug Saf       Date:  2018-06       Impact factor: 5.606

9.  Indomethacin and pancreatic enzymes synergistically damage intestine of rats.

Authors:  R E Kimura; V Arango; J Lloyd-Still
Journal:  Dig Dis Sci       Date:  1998-10       Impact factor: 3.199

10.  Increased gastric juice epidermal growth factor after non-steroidal anti-inflammatory drug ingestion.

Authors:  S M Kelly; J R Jenner; R J Dickinson; J O Hunter
Journal:  Gut       Date:  1994-05       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.